Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.


Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 07 01 2020
revised: 08 04 2020
accepted: 23 04 2020
pubmed: 1 7 2020
medline: 24 12 2021
entrez: 30 6 2020
Statut: ppublish

Résumé

Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth is still a subject of debate. We performed a blind comparison of the kinetics of HCC recurrence in patients after HCV treatment with or without DAA to evaluate the potential aggressiveness of HCC after DAA treatment. Thirty-nine HCV-infected patients from the AFEF/ANRS CO22 Hepather cohort who experienced HCC recurrence after so-called curative treatment were evaluated. Contrast-enhanced CT and/or MR images were read blindly 6 months before HCC recurrence and during the follow-up period. Seventeen patients who received DAA (DAA+) before HCC recurrence were compared to the 22 who did not receive (DAA-), according to the LiRads and mRECIST criteria. There were 28 men and 11 women, median age 62 years old, 37 (95%) with cirrhosis. DAA+ patients had a lower median MELD score (8±2 vs. 10±4, P=0.0286) than DAA- patients. The median time to HCC recurrence (time from the date of curative treatment to the diagnosis of recurrence) was not different (20 vs. 18 months) (P=0.73) between the two groups. There was no difference between the 2 groups in the overall survival and/or transplantation-free survival (P=0.71) and for the mRECIST time to progression (P=0.25). This blinded analysis of HCC recurrence after HCC treatment does not support any negative impact of DAA therapy on the severity or progression of recurrent HCC.

Sections du résumé

BACKGROUND BACKGROUND
Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth is still a subject of debate. We performed a blind comparison of the kinetics of HCC recurrence in patients after HCV treatment with or without DAA to evaluate the potential aggressiveness of HCC after DAA treatment.
BASIC PROCEDURES METHODS
Thirty-nine HCV-infected patients from the AFEF/ANRS CO22 Hepather cohort who experienced HCC recurrence after so-called curative treatment were evaluated. Contrast-enhanced CT and/or MR images were read blindly 6 months before HCC recurrence and during the follow-up period. Seventeen patients who received DAA (DAA+) before HCC recurrence were compared to the 22 who did not receive (DAA-), according to the LiRads and mRECIST criteria.
MAIN FINDINGS RESULTS
There were 28 men and 11 women, median age 62 years old, 37 (95%) with cirrhosis. DAA+ patients had a lower median MELD score (8±2 vs. 10±4, P=0.0286) than DAA- patients. The median time to HCC recurrence (time from the date of curative treatment to the diagnosis of recurrence) was not different (20 vs. 18 months) (P=0.73) between the two groups. There was no difference between the 2 groups in the overall survival and/or transplantation-free survival (P=0.71) and for the mRECIST time to progression (P=0.25).
CONCLUSION CONCLUSIONS
This blinded analysis of HCC recurrence after HCC treatment does not support any negative impact of DAA therapy on the severity or progression of recurrent HCC.

Identifiants

pubmed: 32595103
pii: S2210-7401(20)30152-2
doi: 10.1016/j.clinre.2020.04.022
pii:
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101459

Investigateurs

Delphine Bonnet (D)
Virginie Payssan-Sicart (V)
Chloe Pomes (C)
François Bailly (F)
Marjolaine Beaudoin (M)
Dominique Giboz (D)
Kerstin Hartig-Lavie (K)
Marianne Maynard (M)
Eric Billaud (E)
David Boutoille (D)
Morane Cavellec (M)
Marjorie Cheraud-Carpentier (M)
Isabelle Hubert (I)
Jaouad Benhida (J)
Adrien Lannes (A)
Françoise Lunel (F)
Frédéric Oberti (F)
Nathalie Boyer (N)
Nathalie Giuily (N)
Corinne Castelnau (C)
Giovanna Scoazec (G)
Aziza Chibah (A)
Sylvie Keser (S)
Karim Bonardi (K)
Anaïs Vallet-Pichard (A)
Philippe Sogni (P)
Juliette Foucher (J)
Jean-Baptiste Hiriart (JB)
Amy Wilson (A)
Sarah Shili (S)
Faiza Chermak (F)
Christelle Ansaldi (C)
Nisserine Ben Amara (NB)
Laëtitia Chouquet (L)
Emilie De Luca (E)
Valérie Oules (V)
Rodolphe Anty (R)
Eve Gelsi (E)
Régine Truchi (R)
Elena Luckina (E)
Nadia Messaoudi (N)
Joseph Moussali (J)
Barbara De Dieuleveult (B)
Damien Labarriere (D)
Pascal Poter (P)
Si Nafa Si Ahmed (SNS)
Véronique Grando-Lemaire (V)
Pierre Nahon (P)
Valérie Bourcier (V)
Séverine Brulé (S)
Thomas Stalhberger (T)
Caroline Jezequel (C)
Audrey Brener (A)
Anne Laligant (A)
Aline Rabot (A)
Isabelle Renard (I)
Thomas F Baumert (TF)
Michel Dofföel (M)
Catherine Mutter (C)
Pauline Simo-Noumbissie (P)
Esma Razi (E)
Hélène Barraud (H)
Mouni Bensenane (M)
Abdelbasset Nani (A)
Sarah Hassani-Nani (S)
Marie-Albertine Bernard (MA)
Georges-Philippe Pageaux (GP)
Michael Bismuth (M)
Ludovic Caillo (L)
Stéphanie Faure (S)
Marie-Pierre Ripault (MP)
Christophe Bureau (C)
Jean Marie Peron (JM)
Marie-Angèle Robic (MA)
Léa Tarallo (L)
Marine Faure (M)
Bruno Froissart (B)
Marie-Noelle Hilleret (MN)
Jean-Pierre Zarski (JP)
Odile Goria (O)
Victorien Grard (V)
Hélène Montialoux (H)
Muriel François (M)
Christian Ouedraogo (C)
Christelle Pauleau (C)
Anne Varault (A)
Tony Andreani (T)
Bénédicte Angoulevant (B)
Azeline Chevance (A)
Lawrence Serfaty (L)
Teresa Antonini (T)
Audrey Coilly (A)
Jean-Charles Duclos Vallée (JD)
Mariagrazia Tateo (M)
Corinne Bonny (C)
Chanteranne Brigitte (C)
Géraldine Lamblin (G)
Léon Muti (L)
Abdenour Babouri (A)
Virginie Filipe (V)
Abdenour Babouri (A)
Virginie Filipe (V)
Camille Barrault (C)
Laurent Costes (L)
Hervé Hagège (H)
Soraya Merbah (S)
Paul Carrier (P)
Maryline Debette-Gratien (M)
Jérémie Jacques (J)
Guillaume Lassailly (G)
Florent Artu (F)
Valérie Canva (V)
Sébastien Dharancy (S)
Alexandre Louvet (A)
Marianne Latournerie (M)
Marc Bardou (M)
Thomas Mouillot (T)
Yannick Bacq (Y)
Didier Barbereau (D)
Charlotte Nicolas (C)
Caroline Chevalier (C)
Isabelle Archambeaud (I)
Sarah Habes (S)
Nisserine Ben Amara (NB)
Danièle Botta-Fridlund (D)
Eric Saillard (E)
Marie-Josée Lafrance (MJ)

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Anais Vallet-Pichard (A)

Hepatology Unit, Hôpital Cochin, AP-HP, 27, rue du Fg Saint-Jacques, 75014 Paris, France. Electronic address: anais.vallet-pichard@aphp.fr.

Jean-Michel Correas (JM)

Radiologie Hôpital Necker AP-HP, Paris, France.

Celine Dorival (C)

Sorbonne Université, inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique Sante Publique Hopital Saint-Antoine, AP-HP, Paris, France.

Fabien Zoulim (F)

Hepatologie Hospices Civils de Lyon, inserm, Lyon, France.

Albert Tran (A)

Hepatologie CHU de Nice, Nice, France.

Marc Bourlière (M)

Hepato Gastroenterologie Hôpital Saint-Joseph, Marseille, France.

Paul Calès (P)

Hepato Gastroenterologie CHU Angers, Angers, France.

Dominique Guyader (D)

Hepatologie CHU Rennes, Rennes, France.

Jean-Pierre Bronowicki (JP)

Hepato Gastroenterologie CHU de Nancy, Nancy, France.

Dominique Larrey (D)

Hepato Gastroenterologie Hôpital Saint-Eloi, Montpellier, France.

Christophe Hezode (C)

Hepatologie Hôpital Henri Mondor, AP-HP, Créteil, France.

Veronique Loustaud-Ratti (V)

Hepato Gastroenterologie CHU Limoges, Limoges, France.

Jerome Gournay (J)

Hepato Gastroenterologie Hôpital Hôtel-Dieu, Nantes, France.

Victor de Ledinghen (V)

Hepatologie Hôpital Haut-Lévêque, Pessac, Bordeaux, France.

Tarik Asselah (T)

Hepatologie Hôpital Beaujon, AP-HP, Clichy, France.

Nathalie Ganne (N)

Hepatologie Hôpital Jean-Verdier, AP-HP, Bondy, France.

Sophie Metivier (S)

Hepatologie CHU Purpan, Toulouse, France.

Olivier Chazouillères (O)

Hepatologie Hôpital Saint-Antoine, AP-HP, Paris, France.

Vincent Leroy (V)

Hepatologie CHU de Grenoble, Grenoble, France.

Isabelle Rosa (I)

Hepato Gastroenterologie Centre Hospitalier Intercommunal, Créteil, France.

Didier Samuel (D)

Hepatologie Hôpital Paul-Brousse, AP-HP, Villejuif, France.

Philippe Mathurin (P)

Hepatologie CHRU Claude Huriez, Lille, France.

Carole Cagnot (C)

Inserm ANRS, Paris, France.

Helene Fontaine (H)

Hepatology Unit, Hôpital Cochin, AP-HP, 27, rue du Fg Saint-Jacques, 75014 Paris, France.

Fabrice Carrat (F)

Sorbonne Université, inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique Sante Publique Hopital Saint-Antoine, AP-HP, Paris, France.

Stanislas Pol (S)

Hepatology Unit, Hôpital Cochin, AP-HP, 27, rue du Fg Saint-Jacques, 75014 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH